UNSPSC 51124008: Lorcainide

This classification denotes an antiarrhythmic agent with the molecular formula C22H27ClN2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) KGJ2T0N7IQ, chemically known as r 15,889 but more generally known as lorcainide, which bears US NIH Compound Identifier 42884. European Medicines Agency schedules Lorcainide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08584MIG.

UNSPSC 51124008 Lorcainide is a Commodity code covering specific pharmaceutical products procured by state and local government agencies for emergency medical services, hospital systems, and health benefit programs. State and local governments buy this code to stock emergency medications, support pharmacy benefit initiatives, and supply multi-state cooperative purchasing alliances with branded and generic pharmaceuticals. Recent solicitations show purchasing driven by fire rescue departments, health and human services agencies, and multi-state procurement cooperatives acquiring lorcainide and related advanced life support medications as individual line items within broader medication orders.

Issuing bodies include city fire rescue departments, state health commissions, and multi-state cooperative purchasing organizations. The City of Tampa's Fire Rescue department and the Texas Health and Human Services Commission represent the primary recent buyers. Geographic activity centers on Florida and Texas, with multi-state reach through the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), which administers contracts for participating state and local government facilities across multiple jurisdictions including Oregon. The City of Tampa issued IFB 26P00188 for Advanced Life Support Medications with response due April 8, 2026, requesting 1,020 units of Diltiazem, 370 units of Labetalol, and other specified medications for Tampa Fire Rescue with an estimated contract value of $40,000 and a one-year initial term plus renewal options. MMCAP issued RFP S1070000015802 for Generic Multi Source Pharmaceuticals and OTC Products with response due March 26, 2026, establishing multiple contracts effective July 1, 2026, through authorized wholesalers for two-year terms with optional extensions. The Texas Health and Human Services Commission issued RFI HHS0017013 in March 2026 to gather market intelligence on direct-to-manufacturer prescription programs before launching formal procurement, reflecting state interest in alternative distribution models for pharmaceutical supply.